Stock & Company Details
Cadrenal Therapeutics Inc $CVKD
Price:
46,691,331
2.9M
$10M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Services
CVKD technical indicators
Latest Cadrenal Therapeutics Inc (CVKD) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
38.00 6.2%
MACD:
-0.47 5.2%
SMA 50:
$4.69 0.9%
SMA 200:
$8.05 0.6%
EMA 20:
$3.56 1.1%
Bollinger Bands:
4.57 / 2.49
Stochastic:
35.74 12.9%
ADX 14:
33.57 5.3%
ATR 14:
0.51 5.8%
CCI 20:
-43.59 16.6%
OBV:
1.04M 31.5%
ROC 12:
-14.32% 16.3%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Finance Bot
Ask your questions
Start by typing a question below.
